Surgical treatment of resectable and borderline resectable pancreatic cancer in tertiary cancer center: the 6-year experience
Article Sidebar
Main Article Content
Abstract
Objective: The aim of the study is to analyze the short and long-term results of surgical treatment of resectable and borderline-resectable patients during 2015-2017 (1st period) and 2018-2021 (2nd period).
Material and Methods: A retrospective analysis of patients treated with pancreatic resection with (VR) and without portal or mesenteric vein resection (standard resection, SR) for exocrine pancreatic carcinoma in National Cancer Institute, Kyiv, Ukraine in 2015-2021.
Results: 188 patients underwent surgical treatment, among which 67 received concomitant portal/mesenteric vein resection. Postoperative mortality was 10.04% (14.93% and 6.61% in VR and SR group, respectively, p=0.11). Textbook outcome rate was 67.3% vs 72.7% in VR and SR groups, respectively (p=0.57). Comparing 2015-2017 and 2018-2021 time periods, TO rate did not change for VR – 67.9% vs 66.8% (p>0.99), but tended to increase in SR group – 62.2% vs 80.4% (p=0.089). Median overall survival was 17.03 month and did not differ between VR and SR. OS of all patients differed significantly between 2015-2017 and 2018-2021 – 13.8 vs 22.5 month (p=0.013). In multivariative analysis pancreatic head resection and lower tumor grade were positive prognostic factors, while age >65 and first study period – negative for OS.
Conclusion: Extended due to venous resection pancreatectomies lead to comparable with standard procedures short-term and long-term results. The tumor grade G1-2, patient age less than 65, pancreaticoduodenal resection, and treatment period 2018-2021 were independent factors for better prognosis. Further prospective data is necessary to obtain representative results
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Accepted 2022-05-14
Published 2022-05-27
References
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R., Torre, L. and Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2018;68(6):394-424. DOI: https://doi.org/10.3322/caac.21492
Neoptolemos, J., Stocken, D., Friess, H., Bassi, C., Dunn, J., Hickey, H., Beger, H., Fernandez-Cruz, L., Dervenis, C., Lacaine, F., Falconi, M., Pederzoli, P., Pap, A., Spooner, D., Kerr, D. and Büchler, M. A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic Cancer. New England Journal of Medicine. 2004;350(12):1200-1210. DOI: https://doi.org/10.1056/NEJMoa032295
Klaiber, U., Hackert, T. and Neoptolemos, J. Adjuvant treatment for pancreatic cancer. Translational Gastroenterology and Hepatology. 2019;4:27-27. DOI: https://doi.org/10.21037/tgh.2019.04.04
Bockhorn, M., Uzunoglu, F., Adham, M., Imrie, C., Milicevic, M., Sandberg, A., Asbun, H., Bassi, C., Büchler, M., Charnley, R., Conlon, K., Cruz, L., Dervenis, C., Fingerhutt, A., Friess, H., Gouma, D., Hartwig, W., Lillemoe, K., Montorsi, M., Neoptolemos, J., Shrikhande, S., Takaori, K., Traverso, W., Vashist, Y., Vollmer, C., Yeo, C. and Izbicki, J. Borderline resectable pancreatic cancer: A consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). Surgery. 2014;155(6):977-988. DOI: https://doi.org/10.1016/j.surg.2014.02.001
NCCN. 2022. Guidelines Detail. [online] Available at: <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1455> [Accessed 14 February 2022].
Tran Cao, H., Balachandran, A., Wang, H., Nogueras-González, G., Bailey, C., Lee, J., Pisters, P., Evans, D., Varadhachary, G., Crane, C., Aloia, T., Vauthey, J., Fleming, J. and Katz, M. Radiographic Tumor–Vein Interface as a Predictor of Intraoperative, Pathologic, and Oncologic Outcomes in Resectable and Borderline Resectable Pancreatic Cancer. Journal of Gastrointestinal Surgery. 2013;18(2):269-278. DOI: https://doi.org/10.1007/s11605-013-2374-3
Kim, P., Wei, A., Atenafu, E., Cavallucci, D., Cleary, S., Moulton, C., Greig, P., Gallinger, S., Serra, S. and McGilvray, I. Planned versus unplanned portal vein resections during pancreaticoduodenectomy for adenocarcinoma. British Journal of Surgery. 2013;100(10):1349-1356. DOI: https://doi.org/10.1002/bjs.9222
Miyazaki, M., Yoshitomi, H., Takano, S., Shimizu, H., Kato, A., Yoshidome, H., Furukawa, K., Takayashiki, T., Kuboki, S., Suzuki, D., Sakai, N. and Ohtuka, M., 2017. Combined hepatic arterial resection in pancreatic resections for locally advanced pancreatic cancer. Langenbeck's Archives of Surgery, 402(3), pp.447-456. DOI: https://doi.org/10.1007/s00423-017-1578-5
Delpero, J. and Sauvanet, A., 2020. Vascular Resection for Pancreatic Cancer: 2019 French Recommendations Based on a Literature Review From 2008 to 6-2019. Frontiers in Oncology, 10. DOI: https://doi.org/10.3389/fonc.2020.00040
Strobel, O., Berens, V., Hinz, U., Hartwig, W., Hackert, T., Bergmann, F., Debus, J., Jäger, D., Büchler, M. and Werner, J., 2012. Resection after neoadjuvant therapy for locally advanced, “unresectable” pancreatic cancer. Surgery, 152(3), pp.S33-S42. DOI: https://doi.org/10.1016/j.surg.2012.05.029
Fuhrman, G., Leach, S., Staley, C., Cusack, J., Charnsangavej, C., Cleary, K., El-Naggar, A., Fenoglio, C., Lee, J. and Evans, D., 1996. Rationale for En Bloc Vein Resection in the Treatment of Pancreatic Adenocarcinoma Adherent to the Superior Mesenteric-Portal Vein Confluence. Annals of Surgery, 223(2), pp.154-162. DOI: https://doi.org/10.1097/00000658-199602000-00007
Aramaki M, Matsumoto T, Etoh T, et al. Clinical significance of combined pancreas and portal vein resection in surgery for pancreatic adenocarcinoma. Hepato-gastroenterology. 2003 Jan-Feb;50(49):263-266. PMID: 12630036.
Siriwardana, H. and Siriwardena, A., 2006. Systematic review of outcome of synchronous portal–superior mesenteric vein resection during pancreatectomy for cancer. British Journal of Surgery, 93(6), pp.662-673.
Byun, Y., Han, Y., Kang, J., Choi, Y., Kim, H., Kwon, W., Kim, S., Oh, D., Lee, S., Ryu, J., Kim, Y. and Jang, J., 2019. Role of surgical resection in the era of FOLFIRINOX for advanced pancreatic cancer. Journal of Hepato-Biliary-Pancreatic Sciences, 26(9), pp.416-425.
Kishi, Y., Nara, S., Esaki, M., Hiraoka, N. and Shimada, K., 2019. Feasibility of resecting the portal vein only when necessary during pancreatoduodenectomy for pancreatic cancer. BJS Open, 3(3), pp.327-335.
CHILD CG 3rd, HOLSWADE GR, McCLURE RD Jr, GORE AL, O'NEILL EA. Pancreaticoduodenectomy with resection of the portal vein in the Macaca mulatta monkey and in man. Surg Gynecol Obstet. 1952 Jan;94(1):31-45. PMID: 14893090.
McDermott, W., 1952. A ONE-STAGE PANCREATODUODENECTOMY WITH RESECTION OF THE PORTAL VEIN FOR CARCINOMA OF THE PANCREAS. Annals of Surgery, 136(6), pp.1012-1018. DOI: https://doi.org/10.1097/00000658-195212000-00015
FORTNER, J., KIM, D., CUBILLA, A., TURNBULL, A., PAHNKE, L. and SHILS, M., 1977. Regional Pancreatectomy. Annals of Surgery, 186(1), pp.42-50. DOI: https://doi.org/10.1097/00000658-197707000-00007
FORTNER, J., 1984. Regional Pancreatectomy for Cancer of the Pancreas, Ampulla, and Other Related Sites. Annals of Surgery, 199(4), pp.418-425. DOI: https://doi.org/10.1097/00000658-198404000-00008
Sindelar, W., 1989. Clinical Experience With Regional Pancreatectomy for Adenocarcinoma of the Pancreas. Archives of Surgery, 124(1), p.127. DOI: https://doi.org/10.1001/archsurg.1989.01410010137027
Siriwardana, H. and Siriwardena, A., 2006. Systematic review of outcome of synchronous portal–superior mesenteric vein resection during pancreatectomy for cancer. British Journal of Surgery, 93(6), pp.662-673. DOI: https://doi.org/10.1002/bjs.5368
Katz, M., Pisters, P., Evans, D., Sun, C., Lee, J., Fleming, J., Vauthey, J., Abdalla, E., Crane, C., Wolff, R., Varadhachary, G. and Hwang, R., 2008. Borderline Resectable Pancreatic Cancer: The Importance of This Emerging Stage of Disease. Journal of the American College of Surgeons, 206(5), pp.833-846. DOI: https://doi.org/10.1016/j.jamcollsurg.2007.12.020
Isaji, S., Mizuno, S., Windsor, J., Bassi, C., Fernández-del Castillo, C., Hackert, T., Hayasaki, A., Katz, M., Kim, S., Kishiwada, M., Kitagawa, H., Michalski, C. and Wolfgang, C., 2018. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Pancreatology, 18(1), pp.2-11. DOI: https://doi.org/10.1016/j.pan.2017.11.011
Barnes, C., Chavez, M., Tsai, S., Aldakkak, M., George, B., Ritch, P., Dua, K., Clarke, C., Tolat, P., Hagen, C., Hall, W., Erickson, B., Evans, D. and Christians, K., 2019. Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgery. Surgery, 166(3), pp.277-285. DOI: https://doi.org/10.1016/j.surg.2019.05.010
Maggino, L., Malleo, G., Marchegiani, G., Viviani, E., Nessi, C., Ciprani, D., Esposito, A., Landoni, L., Casetti, L., Tuveri, M., Paiella, S., Casciani, F., Sereni, E., Binco, A., Bonamini, D., Secchettin, E., Auriemma, A., Merz, V., Simionato, F., Zecchetto, C., D’Onofrio, M., Melisi, D., Bassi, C. and Salvia, R., 2019. Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma. JAMA Surgery, 154(10), p.932. DOI: https://doi.org/10.1001/jamasurg.2019.2277
Javed, A., Wright, M., Siddique, A., Blair, A., Ding, D., Burkhart, R., Makary, M., Cameron, J., Narang, A., Herman, J., Zheng, L., Laheru, D., Weiss, M., Wolfgang, C. and He, J., 2018. Outcome of Patients with Borderline Resectable Pancreatic Cancer in the Contemporary Era of Neoadjuvant Chemotherapy. Journal of Gastrointestinal Surgery, 23(1), pp.112-121. DOI: https://doi.org/10.1007/s11605-018-3966-8
Byun, Y., Han, Y., Kang, J., Choi, Y., Kim, H., Kwon, W., Kim, S., Oh, D., Lee, S., Ryu, J., Kim, Y. and Jang, J., 2019. Role of surgical resection in the era of FOLFIRINOX for advanced pancreatic cancer. Journal of Hepato-Biliary-Pancreatic Sciences, 26(9), pp.416-425. DOI: https://doi.org/10.1002/jhbp.648
Kishi, Y., Nara, S., Esaki, M., Hiraoka, N. and Shimada, K., 2019. Feasibility of resecting the portal vein only when necessary during pancreatoduodenectomy for pancreatic cancer. BJS Open, 3(3), pp.327-335. DOI: https://doi.org/10.1002/bjs5.50130
Nigri, G., Petrucciani, N., Pinna, A., Ravaioli, M., Jovine, E., Minni, F., Grazi, G., Chirletti, P., Balzano, G., Ferla, F., De Carlis, L., Tisone, G., Napoli, N., Boggi, U. and Ramacciato, G., 2018. Evolution of pancreatectomy with en bloc venous resection for pancreatic cancer in Italy. Retrospective cohort study on 425 cases in 10 pancreatic referral units. International Journal of Surgery, 55, pp.103-109. DOI: https://doi.org/10.1016/j.ijsu.2018.05.025
Ramacciato, G., Nigri, G., Petrucciani, N., Pinna, A., Ravaioli, M., Jovine, E., Minni, F., Grazi, G., Chirletti, P., Tisone, G., Napoli, N. and Boggi, U., 2016. Pancreatectomy with Mesenteric and Portal Vein Resection for Borderline Resectable Pancreatic Cancer: Multicenter Study of 406 Patients. Annals of Surgical Oncology, 23(6), pp.2028-2037. DOI: https://doi.org/10.1245/s10434-016-5123-5
Ravikumar, R., Sabin, C., Abu Hilal, M., Al-Hilli, A., Aroori, S., Bond-Smith, G., Bramhall, S., Coldham, C., Hammond, J., Hutchins, R., Imber, C., Preziosi, G., Saleh, A., Silva, M., Simpson, J., Spoletini, G., Stell, D., Terrace, J., White, S., Wigmore, S. and Fusai, G., 2017. Impact of portal vein infiltration and type of venous reconstruction in surgery for borderline resectable pancreatic cancer. British Journal of Surgery, 104(11), pp.1539-1548. DOI: https://doi.org/10.1002/bjs.10580
Amini, N., Spolverato, G., Kim, Y. and Pawlik, T., 2015. Trends in Hospital Volume and Failure to Rescue for Pancreatic Surgery. Journal of Gastrointestinal Surgery, 19(9), pp.1581-1592. DOI: https://doi.org/10.1007/s11605-015-2800-9
El Amrani, M., Clement, G., Lenne, X., Farges, O., Delpero, J., Theis, D., Pruvot, F. and Truant, S., 2018. Failure-to-rescue in Patients Undergoing Pancreatectomy. Annals of Surgery, 268(5), pp.799-807. DOI: https://doi.org/10.1097/SLA.0000000000002945
Ahola, R., Sand, J. and Laukkarinen, J., 2020. Centralization of Pancreatic Surgery Improves Results: Review. Scandinavian Journal of Surgery, 109(1), pp.4-10. DOI: https://doi.org/10.1177/1457496919900411
Hyer, J., Beane, J., Spolverato, G., Tsilimigras, D., Diaz, A., Paro, A., Dalmacy, D. and Pawlik, T., 2021. Trends in Textbook Outcomes over Time: Are Optimal Outcomes Following Complex Gastrointestinal Surgery for Cancer Increasing?. Journal of Gastrointestinal Surgery, 26(1), pp.50-59. DOI: https://doi.org/10.1007/s11605-021-05129-4
Song, A., Liu, F., Wu, L., Si, X. and Zhou, Y., 2017. Histopathologic tumor invasion of superior mesenteric vein/ portal vein is a poor prognostic indicator in patients with pancreatic ductal adenocarcinoma: results from a systematic review and meta-analysis. Oncotarget, 8(20), pp.32600-32607. DOI: https://doi.org/10.18632/oncotarget.15938
Nakao, A., Kanzaki, A., Fujii, T., Kodera, Y., Yamada, S., Sugimoto, H., Nomoto, S., Nakamura, S., Morita, S. and Takeda, S., 2012. Correlation Between Radiographic Classification and Pathological Grade of Portal Vein Wall Invasion in Pancreatic Head Cancer. Annals of Surgery, 255(1), pp.103-108. DOI: https://doi.org/10.1097/SLA.0b013e318237872e
Giovinazzo, F., Turri, G., Katz, M., Heaton, N. and Ahmed, I., 2015. Meta-analysis of benefits of portal–superior mesenteric vein resection in pancreatic resection for ductal adenocarcinoma. British Journal of Surgery, 103(3), pp.179-191. DOI: https://doi.org/10.1002/bjs.9969
Elshaer, M., Gravante, G., Kosmin, M., Riaz, A. and Al-Bahrani, A., 2017. A systematic review of the prognostic value of lymph node ratio, number of positive nodes and total nodes examined in pancreatic ductal adenocarcinoma. The Annals of The Royal College of Surgeons of England, 99(2), pp.101-106. DOI: https://doi.org/10.1308/rcsann.2016.0340
Lowder, C., Metkus, J., Epstein, J., Kozak, G., Lavu, H., Yeo, C. and Winter, J., 2018. Clinical Implications of Extensive Lymph Node Metastases for Resected Pancreatic Cancer. Annals of Surgical Oncology, 25(13), pp.4004-4011. DOI: https://doi.org/10.1245/s10434-018-6763-4
Lee, B., Witmond, V., Pereira-Salgado, A., Degeling, K., Shapiro, J., Thomson, B., Ananda, S., McLachlan, S., Knowles, B., Fox, A., Wong, R., Burge, M., Clarke, K., Pattison, S., Nikfarjam, M., Nagrial, A., Zielinski, R., Chee, C., Gibbs, P. and IJzerman, M., 2020. Real-world survival outcomes of using neoadjuvant chemotherapy in pancreatic cancer patients: Findings from the PURPLE clinical registry. Journal of Clinical Oncology, 38(15_suppl), pp.e16755-e16755. DOI: https://doi.org/10.1200/JCO.2020.38.15_suppl.e16755